AVEO Pharmaceuticals (Seite 21)
eröffnet am 11.06.14 13:35:59 von
neuester Beitrag 18.10.22 16:55:22 von
neuester Beitrag 18.10.22 16:55:22 von
Beiträge: 669
ID: 1.195.302
ID: 1.195.302
Aufrufe heute: 0
Gesamt: 74.355
Gesamt: 74.355
Aktive User: 0
ISIN: US0535883070 · WKN: A2P0CL
13,635
EUR
-1,62 %
-0,225 EUR
Letzter Kurs 19.01.23 Tradegate
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 119,40 | +29,92 | |
| 1,2100 | +21,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 13,800 | -13,86 | |
| 4,1900 | -14,49 | |
| 5,2500 | -19,23 | |
| 0,7500 | -27,88 | |
| 0,7500 | -48,28 |
Beitrag zu dieser Diskussion schreiben
Feedback
The European Medicines Agency has cleared once-daily VEGF inhibitor tivozanib under the Fotivda brand name as a front-line treatment in adult RCC patients. That means it can be used in patients whose disease has progressed one line of cytokine therapy with interleukin-2 or interferon, provided they have not previously been treated with other drugs including VEGF or mTOR inhibitors.
The EMA approval is based on the results of the TIVO-1 trial, in which tivozanib was found to be better than Bayer/Onyx's VEGF inhibitor Nexavar (sorafenib) in extending progression-free survival (PFS) with fewer side effects. The FDA thought was not up to scratch when it turned down the drug in 2013, but the EMA's advisory committee interpreted the data differently, recommending approval earlier this year.
http://www.fiercebiotech.com/biotech/aveo-s-phoenix-drug-tiv…
The EMA approval is based on the results of the TIVO-1 trial, in which tivozanib was found to be better than Bayer/Onyx's VEGF inhibitor Nexavar (sorafenib) in extending progression-free survival (PFS) with fewer side effects. The FDA thought was not up to scratch when it turned down the drug in 2013, but the EMA's advisory committee interpreted the data differently, recommending approval earlier this year.
http://www.fiercebiotech.com/biotech/aveo-s-phoenix-drug-tiv…
News out
AVEO Oncology Announces FOTIVDA® (tivozanib) Approved in the European Union for the Treatment of Advanced Renal Cell Carcinomahttp://www.aveooncology.com/wp-content/uploads/2017/08/AVEO-…
Antwort auf Beitrag Nr.: 55.602.991 von Onka2 am 26.08.17 12:54:42Hab auch an Übertreibung gedacht und bin mit 2/3 raus. Der Rest läuft halt noch. Denner hat vielleicht zu früh den Button gedrückt, aber seine Nase lag richtig. 
Antwort auf Beitrag Nr.: 55.602.940 von Eulenfoerster am 26.08.17 12:32:54So gut, dass er letztes Quartal seine letzten Stücke verkauft hat.
Aveo geht ab wie Schmitz Katze.
Denner hatte wiedermal einen guten Riecher!
Sehe Kurse um 10$ bald.
Denner hatte wiedermal einen guten Riecher!
Sehe Kurse um 10$ bald.
Trading Spotlight
img]
jetzt geht es doch langsam runter, muss ich mich weniger über meinen frühen Verkauf ärgern.
die Frage ist, wann sind wieder Kaufkurse? Bis 2 USD könnte es noch fallen.
An Nachrichten ist wohl erstmal wenig zu erwarten, oder?
die Frage ist, wann sind wieder Kaufkurse? Bis 2 USD könnte es noch fallen.
An Nachrichten ist wohl erstmal wenig zu erwarten, oder?
Antwort auf Beitrag Nr.: 55.314.661 von Cyberhexe am 13.07.17 07:02:11anbei eine gute Übersicht über das derzeitig empfohlene Vorgehen bei RCC:
Antwort auf Beitrag Nr.: 55.314.619 von Cyberhexe am 13.07.17 06:47:08
Cabozantinib mit der CABOSUN-Studie dürfte auch bald die Zulassung zur Erstlinienbehandlung von Nierenkrebs erhalten:
"Cabozantinib as First-Line Therapy for Patients with Metastatic Renal Cell Carcinoma with Poor or Intermediate-Risk Characteristics"
http://emjreviews.com/therapeutic-area/oncology/cabozantinib…
Zitat von Cyberhexe: Die Konkurrenz bei Erstlinienbehandlung von RCC ist riesig, so dass Tivozanib es schwer haben wird, sich am Markt zu behaupten, sprich von der Ärzteschaft nur selten angewendet wird:
http://www.onclive.com/web-exclusives/expert-discusses-rapid…
"Expert Discusses Rapid Evolution of RCC Treatment
Danielle Bucco
Published Online: Monday, Jul 10, 2017
...
The treatment paradigm for kidney cancer is undergoing significant change, said Shilpa Gupta, MD, MBBS. While sunitinib (Sutent) and pazopanib (Votrient) remain the standard for first-line therapy, cabozantinib and nivolumab (Opdivo) provide new options in the second-line, and other novel monotherapy and combination approaches are also emerging. The changes bring uncertainty, but also give physicians reason to hope that they’ll soon be able to provide better treatments to their patients.
...
There are many unknowns but this combination does make sense. The first-line treatment landscape will probably change very soon. There are also studies investigating cabozantinib (Cabometyx) plus nivolumab (Opdivo) and nivolumab plus ipilimumab (Yervoy)."
Cabozantinib mit der CABOSUN-Studie dürfte auch bald die Zulassung zur Erstlinienbehandlung von Nierenkrebs erhalten:
"Cabozantinib as First-Line Therapy for Patients with Metastatic Renal Cell Carcinoma with Poor or Intermediate-Risk Characteristics"
http://emjreviews.com/therapeutic-area/oncology/cabozantinib…
Antwort auf Beitrag Nr.: 55.299.979 von invest-2011 am 11.07.17 12:11:17Die Konkurrenz bei Erstlinienbehandlung von RCC ist riesig, so dass Tivozanib es schwer haben wird, sich am Markt zu behaupten, sprich von der Ärzteschaft nur selten angewendet wird:
http://www.onclive.com/web-exclusives/expert-discusses-rapid…
"Expert Discusses Rapid Evolution of RCC Treatment
Danielle Bucco
Published Online: Monday, Jul 10, 2017
...
The treatment paradigm for kidney cancer is undergoing significant change, said Shilpa Gupta, MD, MBBS. While sunitinib (Sutent) and pazopanib (Votrient) remain the standard for first-line therapy, cabozantinib and nivolumab (Opdivo) provide new options in the second-line, and other novel monotherapy and combination approaches are also emerging. The changes bring uncertainty, but also give physicians reason to hope that they’ll soon be able to provide better treatments to their patients.
...
There are many unknowns but this combination does make sense. The first-line treatment landscape will probably change very soon. There are also studies investigating cabozantinib (Cabometyx) plus nivolumab (Opdivo) and nivolumab plus ipilimumab (Yervoy)."
http://www.onclive.com/web-exclusives/expert-discusses-rapid…
"Expert Discusses Rapid Evolution of RCC Treatment
Danielle Bucco
Published Online: Monday, Jul 10, 2017
...
The treatment paradigm for kidney cancer is undergoing significant change, said Shilpa Gupta, MD, MBBS. While sunitinib (Sutent) and pazopanib (Votrient) remain the standard for first-line therapy, cabozantinib and nivolumab (Opdivo) provide new options in the second-line, and other novel monotherapy and combination approaches are also emerging. The changes bring uncertainty, but also give physicians reason to hope that they’ll soon be able to provide better treatments to their patients.
...
There are many unknowns but this combination does make sense. The first-line treatment landscape will probably change very soon. There are also studies investigating cabozantinib (Cabometyx) plus nivolumab (Opdivo) and nivolumab plus ipilimumab (Yervoy)."
Durchsuchen
